Blood-Based Test to Detect, Monitor Prostate Cancer Will Be Used in Major Clinical Trial

Blood-Based Test to Detect, Monitor Prostate Cancer Will Be Used in Major Clinical Trial
3D Signatures announced that a major prostate cancer clinical trial will use its proprietary genome biomarker noninvasive blood-based test to diagnose and monitor prostate cancer patients. The clinical trial, named PRECISE, marks 3D Signatures’ first step to validate and approve its clinical risk-assessment blood-based tests for prostate cancer. The 24-month, randomized, PRECISE clinical trial (NCT02380027) was designed to evaluate

Knowledge is power when living with prostate cancer.

Get access to the web’s leading Prostate Cancer news & insights for as little as 16¢/day.
Subscribe or to access all post and page content.

Leave a Comment

Your email address will not be published. Required fields are marked *